|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
BR112017024770A2
(pt)
*
|
2015-05-21 |
2018-07-31 |
Alligator Bioscience Ab |
polipeptídeos inovadores
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
GB201619648D0
(en)
*
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018098370A1
(en)
*
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
|
US10174122B2
(en)
*
|
2017-01-06 |
2019-01-08 |
Eutilex Co., Ltd. |
Anti-human 4-1BB antibodies and uses thereof
|
|
WO2018133139A1
(zh)
|
2017-01-21 |
2018-07-26 |
宁波知明生物科技有限公司 |
芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
BR112019017241A2
(pt)
*
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
CR20200042A
(es)
*
|
2017-08-01 |
2020-03-03 |
Lilly Co Eli |
Anticuerpos anti-cd137
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
CN111511762B
(zh)
*
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
US12202911B2
(en)
*
|
2017-10-10 |
2025-01-21 |
Numab Therapeutics AG |
Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
４﹘１ｂｂ抗體及其製備方法和應用
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104716A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
CA3086098A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CA3091775A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
CN112020517B
(zh)
|
2018-03-23 |
2024-10-29 |
伊莱利利公司 |
用于与抗pd-l1抗体组合的抗cd137抗体
|
|
CA3095498A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Origincell Therapeutics Co., Ltd. |
Anti-pd-l1 antibody and use thereof
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
AU2019293589A1
(en)
*
|
2018-06-29 |
2021-01-21 |
Alector Llc |
Anti-SIRP-beta1 antibodies and methods of use thereof
|
|
GB201811404D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
EP3823988A1
(en)
|
2018-07-19 |
2021-05-26 |
Eli Lilly and Company |
Bispecific antibodies targeting immune checkpoints
|
|
JP7598312B2
(ja)
|
2018-07-23 |
2024-12-11 |
ハイデルベルク ファーマ リサーチ ゲーエムベーハー |
同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
CN112739718B
(zh)
*
|
2018-09-12 |
2024-11-26 |
祐和医药科技(北京)有限公司 |
抗tnfrsf9抗体及其用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
US12590169B2
(en)
|
2018-10-11 |
2026-03-31 |
Inhibrx Biosciences, Inc. |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
AU2019356573B2
(en)
|
2018-10-11 |
2025-12-18 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
SG11202105152YA
(en)
|
2018-11-30 |
2021-06-29 |
Abl Bio Inc |
Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
|
|
US12227582B2
(en)
|
2019-01-02 |
2025-02-18 |
Qlsf Biotherapeutics Inc. |
CD137 agonist antibodies and uses thereof
|
|
US20220089752A1
(en)
*
|
2019-01-14 |
2022-03-24 |
The Regents Of The University Of California |
Compositions and methods for modulating cellular internalization
|
|
KR20210133261A
(ko)
*
|
2019-02-26 |
2021-11-05 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Bcma에 결합하는 항원 결합 단백질
|
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
WO2020247290A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Academia Sinica |
Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
|
|
BR112021026309A2
(pt)
|
2019-06-26 |
2022-06-07 |
Ap Biosciences Inc |
Anticorpos para ativação de células t
|
|
JP7634001B2
(ja)
|
2019-10-11 |
2025-02-20 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
４－１ｂｂに結合する抗体およびその用途
|
|
CA3165532A1
(en)
*
|
2020-02-05 |
2021-08-12 |
The Board Of Regents Of The University Of Texas System |
Novel lilrb2 antibodies and uses thereof
|
|
EP4137155A4
(en)
*
|
2020-04-17 |
2024-10-30 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd. |
PREPARATION SPECIFICALLY RELATED TO CD137 AND ITS USE
|
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
|
CN113842456B
(zh)
*
|
2020-06-28 |
2022-07-26 |
上海齐鲁制药研究中心有限公司 |
一种抗人4-1bb的单克隆抗体制剂及其用途
|
|
TW202220677A
(zh)
*
|
2020-07-31 |
2022-06-01 |
日商中外製藥股份有限公司 |
含有表現嵌合受體之細胞的醫藥組成物
|
|
CA3217029A1
(en)
|
2021-05-30 |
2022-12-08 |
Biolojic Design Ltd. |
Engineered dual binding antibodies and uses thereof
|
|
WO2023098785A1
(zh)
*
|
2021-12-01 |
2023-06-08 |
上海君实生物医药科技股份有限公司 |
抗4-1bb抗体及其用途
|
|
CN115975032B
(zh)
*
|
2022-12-19 |
2024-06-07 |
华润生物医药有限公司 |
一种cldn18.2抗体及其应用
|
|
WO2025049858A1
(en)
*
|
2023-09-01 |
2025-03-06 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025189194A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against vegf and methods of use thereof
|